DLX6-AS1 is a long noncoding RNA (lncRNA) encoded at chromosome 7 that functions as an oncogenic molecule dysregulated across multiple human malignancies. The gene produces an antisense transcript exceeding 200 nucleotides that acts as a competing endogenous RNA (ceRNA), sponging microRNAs to upregulate downstream tumor-promoting genes 1. Mechanistically, DLX6-AS1 operates at epigenetic, transcriptional, and posttranscriptional regulatory levels, interfering with microRNA axes and signaling pathways including Wnt/β-catenin, Notch, PI3K/AKT/mTOR, and STAT3 2. DLX6-AS1 elevation promotes malignant phenotypes—enhancing cell proliferation, migration, invasion, and epithelial-mesenchymal transformation while suppressing apoptosis 3. Aberrant expression occurs across lung, colorectal, hepatocellular, pancreatic, gastric, ovarian, and breast cancers, among others 4. Clinically, high DLX6-AS1 expression correlates with advanced tumor stage, increased metastasis, and poor overall survival (HR=2.30) 5. Outside oncology, CREB-mediated DLX6-AS1 upregulation contributes to podocyte injury in diabetic nephropathy 6. DLX6-AS1 represents a validated biomarker for cancer diagnosis, prognosis, and a promising therapeutic target across multiple malignancies.